scispace - formally typeset
S

Sheila Scully

Researcher at Amgen

Publications -  44
Citations -  9395

Sheila Scully is an academic researcher from Amgen. The author has contributed to research in topics: Osteoclast & Osteoprotegerin. The author has an hindex of 32, co-authored 44 publications receiving 9041 citations. Previous affiliations of Sheila Scully include University of Tokyo.

Papers
More filters
Journal ArticleDOI

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

TL;DR: Data indicate that OPGL-induced osteoclastogenesis is directly mediated through RANK on osteocLast precursor cells, and polyclonal Ab against the RANK extracellular domain promotes osteoclineogenesis in bone marrow cultures suggesting that RANK activation mediates the effects of OPGl on the osteoc last pathway.
Journal ArticleDOI

T-cell co-stimulation through B7RP-1 and ICOS

TL;DR: A new murine co-stimulatory receptor–ligand pair is described that is structurally related to CD28–B7 and is involved in the adaptive immune response and defined as B7RP-1, which exhibits co- Stimulation activities in vitro and in vivo.
Journal ArticleDOI

The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development

TL;DR: It is reported that mice lacking OPGL or its receptor RANK fail to form lobulo-alveolar mammary structures during pregnancy, resulting in death of newborns and a novel paradigm in mammary gland development and an evolutionary rationale for hormonal regulation and gender bias of osteoporosis in females.
Journal ArticleDOI

Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis

TL;DR: Findings indicate that the OPG/OPGL/RANK signaling pathway may play an important role in both pathological and physiological calcification processes and may also explain the observed high clinical incidence of vascular calcification in the osteoporotic patient population.